Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SSGJ-611 in Chinese Adults With Moderate to Severe Atopic Dermatitis
NCT05544591Phase 2Completed
- Sponsor
- 3S Guojian Pharmaceutical
- Start
- Oct 2022
- Primary completion
- Jul 2023
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of SSGJ-611 in atopic dermatitis (AD), sponsored by 3S Guojian Pharmaceutical. Started Oct 2022; status: completed.
02
Drugs
SSGJ-611
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05544591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05544591.